Aquila and NASA Extend Partnership for Employee Fitness & Wellness Program
The initial collaboration, launched in 2018, allowed Aquila to design and implement a comprehensive health and fitness initiative tailored for NASA's workforce. This extension is a testament to the program's success in fostering a culture of wellness and the ongoing commitment of both organizations to employee health.
The extended program will maintain its collaboration with NASA's Office of the Chief Health and Medical Officer (OCHMO). This partnership ensures a comprehensive approach to wellness, incorporating physical and mental health aspects tailored to the unique needs of NASA's diverse workforce.
Miklin reiterates the importance of a personalized approach to health and fitness. "Our goal is to continue fostering open, respectful dialogues about health, recognizing each employee's unique journey and providing effective strategies to achieve their wellness goals," he said. "This partnership is more than just a fitness program; it's about creating a sustainable, supportive culture that enhances the well-being of employees at NASA."
As Aquila and NASA embark on this extended journey, their combined efforts aim to nurture a workplace environment that prioritizes health, supports personal growth, and contributes to NASA's mission success.
About Aquila
A pioneering force in workplace health and wellness solutions, Aquila boasts 30 years of prowess in designing, developing, and managing workplace amenities, fitness services, and wellbeing engagement. The Aquila model also provides demonstrable ROI through data gathering and reporting.
For Press Inquiries:
Aquila
1221 Brickell Avenue, Suite 1060
T (305) 400-8444
Website: www.aquilaltd.com
Blog: www.aquilaltd.com/blog
E-mail: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/aquila-and-nasa-extend-partnership-for-employee-fitness--wellness-program-302006867.html
SOURCE Aquila
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026
- Major Shareholder Announcement
- Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share